Mid-Sized European Companies Eager to Acquire During Growth Spurt
Among Europe’s flourishing niche of mid-sized pharmaceutical companies, Italy’s Recordati and Spain’s Almirall have snapped up smaller local companies during the past six to nine months, while Switzerland’s Actelion is concentrating on executing new product launches while considering M&A.
You may also be interested in...
News that Europe’s largest biotech Actelion is in preliminary discussions with Johnson & Johnson about a transaction has been viewed favourably by investors, and could see the return of mega-merger activity to other big pharma companies.
The Switzerland-based biotech Actelion is bullish about new indications and labeling updates for its marketed pulmonary arterial hypertension product macitentan, including in CTEPH, and has also unveiled a promising Phase II candidate for resistant hypertension.
Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.